
Lucid Diagnostics (LUCD) Stock Forecast & Price Target
Lucid Diagnostics (LUCD) Analyst Ratings
Bulls say
Lucid Diagnostics is well-positioned to capture a significant market share in the rapidly growing field of esophageal cancer diagnostics, with their highly accurate EsoGuard test and upcoming device EsoCheck. With favorable feedback and plans for expansion, the company's strong financials and promising future products make it a solid investment opportunity with a BUY rating. However, potential obstacles may affect the company's ability to reach its target share price.
Bears say
Lucid Diagnostics is facing several fundamental challenges, including declining test volumes and deferred revenue recognition due to the early stage of their billing and collection process. Additionally, the company is still awaiting a positive Medicare coverage decision for their diagnostic tests, which could significantly impact their potential for growth and profitability. The potential market opportunity for their products is significant, but the company still has a long road ahead in terms of commercialization and overcoming potential risks and obstacles.
This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Lucid Diagnostics (LUCD) Analyst Forecast & Price Prediction
Start investing in Lucid Diagnostics (LUCD)
Order type
Buy in
Order amount
Est. shares
0 shares